School of Medicine, National University of Ireland, Galway, Ireland.
Department of Neonatology, Coombe Women and Infants University Hospital, Cork Street, Dublin 8, Ireland.
Eur J Pediatr. 2019 Jun;178(6):923-928. doi: 10.1007/s00431-019-03373-0. Epub 2019 Apr 4.
Previous studies have identified numerous risk factors associated with necrotizing enterocolitis (NEC) in very low birth weight (VLBW; birth weight less than 1500 g) infants. One of the potential pathophysiological contributors could be antibiotic therapy. Our aim was to explore the association between antibiotic exposure and NEC in VLBW infants. We designed a retrospective 1:2 case-control cohort study in a level III neonatal intensive care unit. Our study group composed of VLBW infants born between January 2012 and December 2014 with a diagnosis of NEC stage IIA or greater (Bell's modified criteria). Our intent was to match every case in the study group to two controls. Our primary outcome was an association between antibiotic exposure and NEC. Twenty-two cases of NEC were matched to 32 controls. The infants who developed NEC were exposed to a statistically significantly more frequent number of antibiotic courses and to more days on any antibiotic prior to the development of NEC. There were significant differences between cases and controls with respect to the duration of exposure to gentamicin and meropenem specifically.Conclusion: The data from our study demonstrate that prolonged exposure to antibiotic therapy is associated with an increased risk of NEC among VLBW infants. Furthermore, gentamicin and meropenem, but not other antibiotics, had a significant association with the incidence of NEC. What is known: • Early antibiotic exposure is a risk factor for the development of necrotising enterocolitis (NEC) in very low birth weight infants • Prolonged initial empirical antibiotic course for ≥ 5 days, despite sterile blood culture, is associated with an increased risk of developing NEC What is new: • The cumulative total number of days of antibiotic exposure is associated with an increased risk of developing NEC • Gentamicin and meropenem, but not other antibiotics, had a significant association with the incidence of NEC in our study.
先前的研究已经确定了许多与极低出生体重(VLBW;出生体重小于 1500 克)婴儿患坏死性小肠结肠炎(NEC)相关的风险因素。潜在的病理生理学因素之一可能是抗生素治疗。我们的目的是探讨暴露于抗生素与 VLBW 婴儿 NEC 之间的关联。我们在三级新生儿重症监护病房设计了一项回顾性 1:2 病例对照队列研究。我们的研究组由 2012 年 1 月至 2014 年 12 月出生的 VLBW 婴儿组成,这些婴儿患有 NEC ⅡA 期或更高级别(改良的贝尔标准)。我们的目的是为研究组中的每个病例匹配 2 个对照。我们的主要结局是抗生素暴露与 NEC 之间的关联。22 例 NEC 患儿与 32 例对照患儿相匹配。发生 NEC 的婴儿接受抗生素治疗的疗程和使用任何抗生素的天数明显多于未发生 NEC 的婴儿。在暴露于庆大霉素和美罗培南的时间长短方面,病例组与对照组存在显著差异。结论:本研究的数据表明,抗生素治疗时间延长与 VLBW 婴儿 NEC 风险增加相关。此外,庆大霉素和美罗培南,而不是其他抗生素,与 NEC 的发生有显著关联。已知:• 早期暴露于抗生素是极低出生体重儿发生坏死性小肠结肠炎(NEC)的一个危险因素• 尽管血培养无菌,但初始经验性抗生素疗程延长至≥5 天,与发生 NEC 的风险增加相关未知:• 抗生素暴露的总天数与发生 NEC 的风险增加相关• 在我们的研究中,庆大霉素和美罗培南与 NEC 的发生率有显著关联,而其他抗生素则没有